Search 

Research Projects

The Body Composition Analysis Center offers an array of specific services to researchers, each tailored to particular study needs. We have served as a reading center for the following studies:

This is only a partial list.

ACTG 5005

Dates of Study: October 1998-November 1999
Study Title: “Study of protease inhibitor and/or non-nucleoside reverse transcriptase inhibitor with dual nucleosides in initial therapy of HIV Infection: A Multicenter Trial of the Adult AIDS Clinical Trials Group”
Study Description: In this large, multicenter study comparing 6 different initial treatment strategies, AZT + 3TC + efavirenz emerged clearly superior to the other 5 combinations, including 4-drug triple-class regimens.
Study Locations: 58 sites in the U.S. and 23 sites in Italy
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5079

Dates of study: February 2001-December 2008
Study Title: “A Prospective, Multicenter, Randomized, Placebo-Controlled Trial of Physiologic Testosterone Supplementation for HIV-positive Men with Mildly to Moderately Reduced Serum Testosterone Levels and Abdominal Obesity”
Study Description: The main purpose of A5079 was to find out whether treatment with testosterone gel could decrease abdominal visceral fat in HIV-positive men with abdominal obesity and reduced testosterone levels. The study also evaluated the effect of testosterone replacement on total body fat, subcutaneous fat and lean body mass. Eighty-eight HIV-positive men with abdominal obesity and reduced testosterone levels participated in this study.
The initial results of this study show that, contrary to our expected results, testosterone replacement as used in this study had NO effect on reducing abdominal visceral fat.  Testosterone did lead to an overall decrease in total body fat and in total subcutaneous fat and was associated with an increase in lean body mass. The team is awaiting the results of additional blood tests (testosterone and other hormone levels as well as lipid, glucose and insulin levels) that may help us better understand the results of this study. 
Study Locations: 24 U.S sites and 1 Puerto Rico site
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5110

Dates of study: May 2002-March 2005
Study Title: “A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the effect a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting”
Study Description: The goals of this study are to find out if fat wasting and weight loss in the arms and legs of HIV patients taking highly active antiretroviral therapy (HAART) are caused by nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and if wasting can be reversed if the NRTI is stopped and replaced with other anti-HIV drugs
Study Locations: 22 U.S sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5116/ACTG 5124/ACTG 5125

Dates of study: August 2001-March 2003
Study Title: “Visceral Adipose Tissue Substudy: Effects of PI-Containing/NRTI-Sparing and NRTI-Containing/PI Sparing Regimens on Visceral Adipose Tissue Cross-Sectional Area A Substudy of A5116”
Study Description: This study will examine the effects of PI-containing/NRTI-sparing and NRTI-containing/PI-sparing regimens on visceral fat content in individuals with HAART-associated visceral adiposity.  Participants will be asked to undergo a noncontrast CT scan at the level of L4, L5 at entry and at week 48 of the main study, A5116.  At a central reading center, the CT scans will be analyzed for cross-sectional area of visceral fat.  The primary objective is to examine the changes in visceral fat from entry to week 48 within each of the two arms defined by the parent study.  A total-body DEXA will also be done to assess the concomitant changes in total and peripheral subcutaneous fat content during the same study period.
Study Locations: U.S sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5142

Dates of Study: February 2003- October 2006
Study Title: “A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs for the Initial Therapy for HIV-1 Infection.”
Sponsor: The National Institute of Allergy and Infectious Diseases (NIAID)
Study Description:  This study was conducted in order to compare the effectiveness of three different HIV treatment regimens (the regimens will be based either lopinavir/ritonavir, NNRTIs, or a nucleoside-sparing medication). Approximately 660 participants were enrolled for 96 weeks beyond the date of the last enrolled subject. Secondary objectives included comparing degrees of lipoatrophy measure by DEXA and to note any associated metabolic disorders such as truncal fat accumulation, hypercholesterolemia, and insulin resistance.  
There were a few significant findings from this study. Efavirenz was found to intensify the lipoatrophic effect of NRTIs more than lopinavir/ritonavir. Zidovudine was also found to yield more fat wasting in the extremities than tenofovir. Efavirenz was not linked to lipoatrophy when combined with lopinavir/ritonavir. This suggested that lipoatrophy is either linked to use of NRTIs or that lopinavir/ritonavir prevent it in some way.

Tufts was contracted in 2003 to analyze whole body DEXA scans.
Study Locations: 60 U.S sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5148

Dates of Study:  2003- February 2005
Study Title: “A Pilot Study of the Safety, Efficacy and Tolerability of Extended-Release Niacin (Niaspan®)for Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects.”
Study Description:  Lipid disorders are common among patients with HIV and tend to worsen with potent antiretroviral therapy. Lipid-lowering drugs are not always effective, and few data address interactions between antiretroviral drugs and lipid-lowering agents. Additional agents for the treatment of lipid metabolism disorders in HIV-infected patients are needed. Niacin, which is highly effective for similar lipid disorders in the general population, may be effective in treating lipid disorders in patients with HIV.

This 48-week study consists of two steps. In Step 1, patients will begin a lipid-lowering diet and exercise regimen that will continue throughout the study. After 4 weeks on the regimen, patients will enter Step 2 of the study and will begin extended-release niacin therapy. During Step 2, niacin will be dose-escalated every 4 to 6 weeks over a 16-week period. At Weeks 14 and 20, the niacin dose will be determined by blood fat levels. Patients will remain on the dose set at Week 20 for the remainder for the study. If blood tests taken at Week 24 show that blood fat levels have not improved significantly, patients have the option of adding another fat-lowering drug to their therapy.

Patients will visit the clinic at entry and at Weeks 4, 8, 12, 18, 24, 32, 40, and 48. Patients may be asked to come to the clinic at Weeks 14 and 20 to receive additional study drug. Patients must fast for 8 to 12 hours before the screening visit and before each study visit in which blood will be drawn. Blood will be drawn throughout the study for fat, sugar, and insulin tests and for CD4 and CD8 cell counts.
Study Locations: 16 U.S sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5163

Dates of Study: November 2003- April 2006
Study Title: “The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients.”
Study Description:  Decreased bone mineral density (BMD) has been identified in up to 50% of HIV infected men, with severe osteoporosis in up to 21% of these men. The mechanisms underlying these bone abnormalities remain unclear. Bisphosphonates are potent bone resorption inhibitors and have been shown to be effective in treating osteoporosis. While several bisphosphonates are approved for the treatment of osteoporosis in women, alendronate is the only bisphosphonate approved for treatment in men. This study hypothesizes that alendronate will be able to reverse decreased BMD secondary to inhibition of bone resorption in HIV infected patients treated with potent antiretroviral therapy, and that these patients will be able to tolerate alendronate without any significant toxicities. The study will also examine the efficacy of once-weekly alendronate with daily calcium and vitamin D in both men and women with HIV.

Patients will participate in this study for 48 weeks. Patients will be randomly assigned to receive either alendronate or placebo. All patients will receive calcium and vitamin D. Dual energy x-ray absorptiometry (DEXA) scans will be used to evaluate bone density at each visit. After study entry, patients will have visits at Weeks 2, 12, 24, 36, and 48. During these visits, blood will be drawn and a pregnancy test may be performed. Patients must fast for at least 8 hours prior to the entry visit and for the visits at Weeks 2, 12, 24, and 48.
Study Locations: 28 U.S sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5202

Dates of Study: September 2005- December 2007
Study Title: “A Phase IIIB, Randomized, Trial of Open-Label Efavirenz or Atazanavir with Ritonavir in Combination with Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naïve Subjects.”
Study Description:This study was designed to test the efficacy, safety, and tolerability of the above medications as an initial therapy for HIV-1 infected subjects. The study group consists of 1800 HIV infected men and women age 16 or older who will participate for 96 weeks past the date of the last subject to enroll. Participants were assigned to one of four subgroups and some were offered the chance to participate in the A5224s metabolic substudy. Secondary objectives include evaluating drug resistance patterns and occurrence of dyslipidemia,
Study Locations: 63 US sites, 1 P.R. site
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

ACTG 5224s

Dates of Study: October 2005-present
Study Title: “Long-Term Metabolic Assessments in Subjects Treated with Emtricitabine/ Tenofovir or Abacavir/Lamivudine with either Efavirenz or Atazanavir with Ritonavir: A Metabolic Substudy of A5202.”
Study Description: It consists of 250 subjects following a similar protocol to A5202. This study is more concerned with the changes in limb fat and bone mineral density. In 2005, Tufts was contracted by Social and Scientific Systems, Inc. to analyze whole body, hip, and spine DEXAs as well as CT images.
Study Locations: 63 US sites, 1 P.R. site
Statement of Work: Scope- Tufts shall centrally collect, translate, log, read, and perform quantitative analysis from CT (abdominal) and DEXA (wholebody, hip, spine) images for each time-point to be conducted as part of the AACTG metabolic Study. Site Direction- Tufts shall provide direction and technical assistance to sites in the transfer of digital CT and DEXA data and agrees to assure standardization across Sites of CT and DEXA imaging and transfer procedures important for quality control prior to the initiation of the Study; includes data quality control, accessioning, monthly data reporting, data recording and transmission, and phantom circulation and analysis.

ACTG 5229

Dates of Study: January 2006- December 2008
Study Title: “A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy.”
Study Description: This study consists of 164 subjects (men and women age 18 + with HIV-1 and lipoatrophy). Subjects will either be assigned to the experimental group taking NucleomaxX ( a uridine supplement), or to a control group taking a placebo. It is hypothesized that subjects on the experimental regimen will exhibit an increase in limb fat after the 48 week trail period. Tufts was contracted by Case Western University in 2006 to analyze whole body DEXAs for this study.
Study Locations: 40 U.S. sites and 1 P.R. site
Statement of Work: Scope- Tufts shall centrally collect, translate, log, read, and perform quantitative analysis from whole body DEXA images for each time-point to be conducted as part of AACTG 5229 Study. Site Direction- Tufts shall provide direction and technical assistance to sites in the transfer of digital DEXA data and agrees to assure standardization across Sites of DEXA imaging and transfer procedures important for quality control prior to the initiation of the Study; includes data quality control, accessioning, monthly data reporting, data recording and transmission, and phantom circulation and analysis.

Abbott 384

Dates of study: August 2002-September 2007
Study Title: “A Phase II Study of Lopinavir/Ritonavir in Combination with Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral Naïve, HIV-Infected Subjects”
Study Description: The objectives of this study are to explore the metabolic toxicities associated with lopinavir/ritonavir (LPV/r) plus saquinavir mesylate (INV) versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the overall safety, tolerability and efficacy of LPV/r plus INV versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the pharmacokinetics of 400 mg INV taken twice a day (BID), 600 mg INV BID and 800 mg INV BID in combination with 400 mg lopinavir/100 mg ritonavir plus 150 mg lamivudine/300 mg zidovudine BID.  The primary outcome measures of this study were the proportion of subjects with plasma HIV RNA levels below 50 copies/mL.  The time frame was 48 weeks and there were 30 subjects enrolled.
Study Locations: California, Massachusetts, North Carolina, Ottawa, Canada
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

Abbott 613

Dates of Study: January 2004-June 2006
Study Title: “A randomized, open-label, study assessing safety, tolerability, efficacy, and metabolic effects of a simplified lopinavir/ritonavir-based induction/maintenance therapy in antiviral-naïve HIV-infected subjects.”
Study Description: This study conducted by Abbott Laboratories sought to compare the safety, tolerability, antiviral activity, and metabolic effects of a PI regimen and an RTI only regimen. Forty sites in the US, Canada, and Europe enrolled 150 study subjects (men and women age 18+) in a 96 program. The study ran from 2004 until 2006. Tufts University analyzed whole body DEXAs throughout the duration of the study. 
Study Locations: Thirty-three (33) investigators in 5 countries: USA, Canada, United Kingdom, France and Spain.
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

BMS 034

Dates of Study: May 2000-February 2003
Study Title: “A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine.”
Study Description: This is a multinational, 2-arm study. Patients in 1 arm receive BMS-232632 plus EFV placebo capsules. Patients in the other arm receive EFV plus BMS-232632 placebo. Both arms also receive a fixed dose of ZDV-3TC.
Study Locations: 28 U.S. sites, Austria, Belgium, Canada, Chile, Costa Rica, France, Germany, Guatemala, Hungary, Israel, Italy, Malaysia, Panama, Peru, Portugal, P.R., Russia, South Africa, Spain, Switzerland, Thailand, U.K., Venezuela
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

BMS 043

Dates of Study: November 2001-November 2003
Study Title: “A Randomized Open-Label Study of the Antiviral Efficacy and Safety of
Atazanavir versus Lopinavir/Ritonavir (LPV/RTV), Each in Combination with Two Nucleosides in Subjects who Have Experienced Virologic Failure with Prior Protease Inhibitor-Containing HAART Regimen(s)”
Study Description: This is the second report of data analyses conducted through Week 24 for Study AI424043. The first Week 24 report reported efficacy analyses collected on the first 229 subjects randomized through 02-Apr-02, as well as safety analyses conducted on all 290 treated subjects. This current report provides efficacy and safety results from analyses of data from all 300 randomized and 290 treated subjects. The data cut-off for this report occurred prior to dissemination of the results from the first analyses. Therefore, data do not reflect actions taken as a result of prior analyses.
Study Locations: 39 sites in North America, 14 in South America, 14 in Europe,
1 in Australia
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

BMS 077

Dates of Study: December 2004-February 2004
Study Title: “Atazanavir for HIV infected individuals completing atazanavir clinical trials: An Extended Access Study”
Study Description: The purpose of this clinical research study is to provide atazanavir to patients infected with human immunodeficiency virus (HIV) whose antiviral medications are no longer working to control HIV activity within the body and who are unable to create a new treatment regimen using other available anti-HIV drugs, because of either side effects or treatment failure previously taken. The safety of this treatment will also be studied.
Study Locations: 163 sites in U.S., 2 P.R. sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

BMS 089

Dates of Study: January 2004- December 2006
Study Title: “A Phase IV Randomized, Open Label, Multicenter Study of the Antiviral Efficacy and Safety of Atazanavir, With and Without Ritonavir, in combination With Lamivudine and Stavudine XR in Antiretroviral Naïve Subjects”
Study Description: This study was designed to compare the efficacy and safety of two different combinations of antiretroviral medications. Approximately 200 participants were enrolled in the 96 week study. Tufts was contracted by Bristol-Myers Squibb Pharmaceutical Research Institute in 2004 to analyze CTs and whole body DEXAs.

Researchers concluded that the efficacy of both medication combinations was similar, both were well tolerated and relatively safe. However, it was noted that the group taking ritonavir did exhibit a higher rate of hyperbilirubinemia. 
Study Locations: 30 U.S. sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

BMS v253

Dates of Study: December 2004- January 2007
Study Title: “A 48-Week Open-Label Study to Evaluate the Effect of Standard dose Stavudine (d4T) Substitution with Low-Dose d4T in HIV-Infected Subjects with Identified Risk for Mitochondrial Toxicities who have Achieved Virologic Suppression.  ”
Study Description: To evaluate the virologic effect of substitution of standard dose d4T with low dose d4T, as assessed by the proportion of subjects with HIV RNA levels < 50 compies/mL at 48 weeks.
Study Locations: 4 U.S. sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

CRI-STARS

Dates of Study: September 2004- January 2006
Study Title: “An Exploratory Study of the Pharmakinetics, Safety and Antiviral Activity of Once-daily Atazanavir, Saquinavir and Mini-Dose Ritonavir in HIV + Subjects, Including Those Previously Suppressed on Saquinavir/Lopinavir/Ritonavir [stARS]”
Study Description: None provided
Study Locations: 1 U.S. site
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

CARE-001 (Merck)

Dates of Study: August 2008- present
Study Title: “Phase 2 Study of Raltegravir as Replacement for PI or NNRTI based ART in Women with Fat Accumulation (CARE001)”
Study Description: This two-armed study will enroll 40 HIV-1 infected women (20 per arm) for 48 weeks to examine the effects that raltegravir has on visceral adipose tissue. It is hypothesized that the group that uses raltegravil will exhibit a 10% reduction in visceral adipose tissue. In 2008, Tufts was contracted by UCLA to analyze single slice abdominal CTs for this study.
Study Locations: 2 U.S. sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of CT scans. Tufts will provide UCLA key personnel with reports as requested during the course of the project to monitor the progress.

Genetech L2672g

Dates of Study: April 2004- June 2007
Study Title: “A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis”
Study Description: Subjects enrolled: 68 children between the ages of 5 and 13 with cystic fibrosis.  This 18 month study was designed to test the effects of Nutropin AQ on height restricted children with CF. The experimental group taking Nutropin AQ exhibited accelerated height and an increase in lean body mass. No statistical differences between groups were cited with respect to pulmonary function. Nutropin AQ was found to induce insulin resistance in some subjects. Overall, the medication had no serious adverse side effects.
Study Locations: 24 U.S. sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

Genetech F0696g

Dates of Study: January 1997- September 1997
Study Title: “A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multidose Stdy of the Safety and Pharmakinetic/Pharmacodynamic Effects of rhIGF-1 Administered Twice Daily for the Treatment of Type II Diabetes Mellitus in Subjects Receiving Glyburide Treatment”
Study Description: None provided
Study Locations: 27 U.S. sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

IATEC BASIC

Dates of Study: February 2006- September 2008
Study Title: “A Randomized, Controlled, Open-Label, 48-Week Study to Asses Differences in Plasma Lipid Profile Between Patients on Saquinavir/Ritonavir or Atazanavir/Ritonavir in Combination with Tenofovir Disoproxil Fumarate and Emtricitabine as a First-line Regimen.”
Study Description: A total of 120 subjects (male and female, HIV-1 infected individuals over 18 years of age) had enrolled into this 48 week long study to assess the effects of two different combinations of antiretroviral medications. The main concerns were to evaluate changes in plasma lipids, fat redistribution, glucose metabolism, and renal function as a result of the differing medications. Tufts was contracted in 2006 by IATEC to analyze whole body DEXAs and abdominal CTs for this study.
Study Locations: 11 Netherlands sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.

IATEC PREPARE

Dates of Study: February 2006- present
Study Title: “A Randomized, Controlled, Open-Label, 48 Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.”
Study Description: The main objective of PREPARE is to investigate changes in limb fat resulting from antiretroviral therapy. The two above medication combinations will be examined. Groups will consist if subjects who have been using zidovudine plus lamivudine for atleast two years. One group will remain on the current medication regimen, while a second will be switched to using emtricitabine and tenofovir disoproxil fumarate. It is hypothesized that the second group that switched medications will exhibit a mean increase in limb fat. 120 HIV-1 infected subjects over the age of 18 will be monitored for a 48 week time period. In 2006, Tufts was contracted by the International Anti-Viral Therapy Evaluation Centre B.V. (IATEC) to analyze whole body DEXAs as well as single slice abdominal CTs. 
Study Locations: 12 Netherlands sites
Statement of Work: Tufts will provide all necessary and qualified personnel, equipment, material and facilities to provide the services for the Research, namely, the analysis of DEXA and CT scans. Tufts will provide key personnel with reports as requested during the course of the project to monitor the progress.